1. Home
  2. TARS vs NEO Comparison

TARS vs NEO Comparison

Compare TARS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TARS
  • NEO
  • Stock Information
  • Founded
  • TARS 2016
  • NEO 2001
  • Country
  • TARS United States
  • NEO United States
  • Employees
  • TARS N/A
  • NEO N/A
  • Industry
  • TARS Medicinal Chemicals and Botanical Products
  • NEO Precision Instruments
  • Sector
  • TARS Health Care
  • NEO Health Care
  • Exchange
  • TARS Nasdaq
  • NEO Nasdaq
  • Market Cap
  • TARS 1.8B
  • NEO 2.1B
  • IPO Year
  • TARS 2020
  • NEO 1999
  • Fundamental
  • Price
  • TARS $44.83
  • NEO $15.04
  • Analyst Decision
  • TARS Strong Buy
  • NEO Strong Buy
  • Analyst Count
  • TARS 5
  • NEO 9
  • Target Price
  • TARS $54.20
  • NEO $19.89
  • AVG Volume (30 Days)
  • TARS 1.1M
  • NEO 792.3K
  • Earning Date
  • TARS 11-13-2024
  • NEO 11-05-2024
  • Dividend Yield
  • TARS N/A
  • NEO N/A
  • EPS Growth
  • TARS N/A
  • NEO N/A
  • EPS
  • TARS N/A
  • NEO N/A
  • Revenue
  • TARS $129,621,000.00
  • NEO $644,118,000.00
  • Revenue This Year
  • TARS $852.60
  • NEO $12.93
  • Revenue Next Year
  • TARS $74.21
  • NEO $9.70
  • P/E Ratio
  • TARS N/A
  • NEO N/A
  • Revenue Growth
  • TARS 801.96
  • NEO 12.06
  • 52 Week Low
  • TARS $15.60
  • NEO $12.77
  • 52 Week High
  • TARS $52.99
  • NEO $21.22
  • Technical
  • Relative Strength Index (RSI)
  • TARS 57.98
  • NEO 52.58
  • Support Level
  • TARS $46.22
  • NEO $13.35
  • Resistance Level
  • TARS $52.99
  • NEO $16.60
  • Average True Range (ATR)
  • TARS 3.62
  • NEO 0.67
  • MACD
  • TARS -0.33
  • NEO 0.18
  • Stochastic Oscillator
  • TARS 42.09
  • NEO 53.98

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

About NEO NeoGenomics Inc.

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Share on Social Networks: